At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Diamondback 360 Extended Length Orbital Atherectomy Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Radial accEss for nAvigation to Your CHosen Lesion for Peripheral Vascular Intervention: REACH PVI
In Brief
An observational study evaluating Diamondback 360 Extended Length Orbital Atherectomy System for Peripheral Artery Disease. Completed, enrolled 50 participants across 6 sites.
Detailed Summary
The objective of this study is to evaluate acute clinical results of orbital atherectomy (OA) via radial artery access, including complication rates and cost effectiveness.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedMay 9, 2019
Enrollment StartJun 11, 2019
Primary CompletionDec 11, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.1 years ago
Interventions
Diamondback 360 Extended Length Orbital Atherectomy Systemdevice
All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.